Related Experiment Videos
Molecular approaches to prevention and therapy of aerodigestive tract cancers
Abstract:
We describe studies defining several molecular events in human non-small-cell lung cancer (NSCLC). These include increased growth factor and growth factor receptor expression and oncogene alterations. The epidermal growth factor receptor (EGFR) and erbB2 are expressed by NSCLC cells. Transforming growth factor-alpha (TGF-alpha) is produced by NSCLC and may mediate autocrine growth stimulation. Specific inhibition of K-ras oncogene expression by an antisense K-ras construct reduces the growth rate and tumorigenicity of NSCLC cells. Studies with antisense p53 in NSCLC with a homozygous p53 mutation suggest that the presence of the mutant form contributes to the transformed state.
Insights
Researchers identified key molecular changes in non-small-cell lung cancer (NSCLC), including altered growth factors and oncogenes like EGFR and K-ras. Targeting these, such as with antisense K-ras, can reduce tumor growth and tumorigenicity.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Non-small-cell lung cancer (NSCLC) is characterized by complex molecular alterations.
- Growth factor signaling pathways are frequently dysregulated in NSCLC.
- Oncogene activation and tumor suppressor gene mutations play critical roles in NSCLC development.
Purpose of the Study:
- To define key molecular events driving human non-small-cell lung cancer (NSCLC).
- To investigate the role of specific oncogenes and growth factors in NSCLC.
- To explore the therapeutic potential of targeting molecular alterations in NSCLC.
Main Methods:
- Analysis of growth factor and growth factor receptor expression in NSCLC cells.
- Investigation of oncogene alterations, including epidermal growth factor receptor (EGFR), erbB2, and K-ras.
- Utilizing antisense K-ras constructs to inhibit K-ras oncogene expression.
- Studying the impact of antisense p53 on NSCLC cells with p53 mutations.
Main Results:
- Increased expression of growth factors and growth factor receptors (e.g., EGFR, erbB2) was observed in NSCLC.
- Transforming growth factor-alpha (TGF-alpha) production by NSCLC cells suggests autocrine growth stimulation.
- Specific inhibition of K-ras oncogene expression using an antisense K-ras construct led to reduced NSCLC growth rate and tumorigenicity.
- Studies with antisense p53 indicated that mutant p53 contributes to the transformed state in NSCLC.
Conclusions:
- Molecular events such as altered growth factor signaling and oncogene mutations are crucial in NSCLC.
- Targeting specific oncogenes like K-ras holds therapeutic promise for NSCLC treatment.
- The mutant p53 form appears to be a significant contributor to the malignant phenotype in NSCLC.